Treatment of Severe COVID-19 Patients Using Secretome of Hypoxia-Mesenchymal Stem Cells in Indonesia
Status:
Recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
In this randomized controlled trial (RCT), severe cases of COVID-19 infection will be treated
with secretome of hypoxia-mesenchymal stem cells. The improvement in clinical, laboratory,
and radiological manifestations will be evaluated in treated patients compared with the
control group.